Browse by Poster Presenter

Schedule at a Glance

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

O
O’Nians Michalowicz, Rose

Adaptimmune
(P 337) POOLED ANALYSIS OF TRABECTEDIN EFFICACY IN MYXOID/ROUND CELL LIPOSARCOMA FROM THREE PROSPECTIVE CLINICAL TRIALS
Rose O’Nians Michalowicz
Favorite
Obeidin, Farres

Robert H. Lurie Comprehensive Cancer Center of Northwestern University
(P 183) ACTIONABLE GENOMICS IN GASTROINTESTINAL STROMAL TUMORS LACKING KIT OR PDGFRA MUTATIONS.
Farres Obeidin
Favorite
(P 236) EXCEPTIONAL RESPONSE TO COMBINATION IMMUNOTHERAPY WITH YH001 AND ENVAFOLIMAB IN METASTATIC SARCOMA.
Farres Obeidin
Favorite
Oberoi, Sapna

CancerCare Manitoba
(P 250) OUTCOME OF INFANTS WITH RHABDOMYOSARCOMA: A REPORT FROM THE INTERNATIONAL SOFT TISSUE SARCOMA CONSORTIUM
Sapna Oberoi
Favorite
O'Brien, Carmel

KU Leuven
(P 69) EPIDEMIOLOGY AND POTENTIAL CLINICAL RELEVANCE OF TOP1 AND TOP2A TOPOISOMERASES EXPRESSION IN SOFT TISSUE SARCOMA
Carmel O'Brien
Favorite
Ochs, Christina

The Life Raft Group
(P 190) TEMPORAL DECLINE IN PROGRESSION-FREE SURVIVAL, TIME ON MEDICATION, AND OVERALL SURVIVAL IN ADVANCED GASTROINTESTINAL STROMAL TUMOR
Christina Ochs
Favorite
Odeniyide, Patience

Johns Hopkins University
(P 405) PAN-RAS INHIBITION AS A NOVEL THERAPEUTIC STRATEGY FOR RAS-DRIVEN RHABDOMYOSARCOMA
Patience Odeniyide
Favorite
Offer, Katharine

Department of Pediatrics, Hackensack Meridian School of Medicine, Hackensack Meridian Health
(P 251) SPATIAL MULTI-OMIC ANALYSIS OF RHABDOMYOSARCOMA IDENTIFIES THERAPEUTIC VULNERABILITIES
Katharine Offer
Favorite
Ogawa, Chitose

Department of Pediatric Oncology, National Cancer Center Hospital
(P 271) SAFETY AND EFFICACY OF CABOZANTINIB IN PEDIATRIC PATIENTS WITH MALIGNANT SOLID TUMORS (CAMEL TRIAL/NCCH2106): A SINGLE-CENTRE PHASE I TRIAL
Chitose Ogawa
Favorite
(P 341) PROGNOSTIC RELEVANCE OF CYCLOPHOSPHAMIDE DOSE FOR HIGH-RISK RHABDOMYOSARCOMA IN ADULT PATIENTS TREATED WITH VAC THERAPY
Chitose Ogawa
Favorite
Oghumu, steve

The Ohio State University Wexner Medical Center
(P 153) DOES THE QUANTITY OF DEDIFFERENTIATION MATTER IN THE CLINICAL OUTCOMES OF DEDIFFERENTIATED CHONDROSARCOMA? A 10-YEAR SINGLE TERTIARY INSTITUTIONAL EXPERIENCE OF A SERIES.
steve Oghumu
Favorite
Ogura, Koichi

National Cancer Center Hospital
(P 159) CHONDROSARCOMA IN JAPAN: A POPULATION-BASED ANALYSIS USING NATIONAL CANCER REGISTRY
Koichi Ogura
Favorite
Oh, David

University of California, San Francisco
(P 439) AN OPEN LABEL MULTICENTER PHASE 2 STUDY WITH SAFETY LEAD IN OF INTRATUMORAL VUSOLIMOGENE ODERPAREPVEC IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANGIOSARCOMA
David Oh
Favorite
Oh, Nakyung

MD Anderson Cancer Center
(P 172) COMPARISON OF CELL SEGMENTATION METHODS IN SOFT TISSUE SARCOMA (STS) SPATIAL PROTEOMIC DATASETS
Nakyung Oh
Favorite
Okimoto, Ross

UCSF Helen Diller Family Comprehensive Cancer Center
(P 439) AN OPEN LABEL MULTICENTER PHASE 2 STUDY WITH SAFETY LEAD IN OF INTRATUMORAL VUSOLIMOGENE ODERPAREPVEC IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANGIOSARCOMA
Ross Okimoto
Favorite
Okuno, Scott

Mayo Clinic
(P 223) OUTCOMES OF GERIATRIC PATIENTS WITH DE NOVO SARCOMA AND LUNG METASTASES: ROLE OF TUMOR CHARACTERISTICS AND TREATMENT STRATEGY
Scott Okuno
Favorite
(P 246) CTLA4 PATHWAY ACTIVATION IN RADIATION-INDUCED ANGIOSARCOMA: A TRANSCRIPTOMIC RATIONALE FOR IMMUNE CHECKPOINT BLOCKADE
Scott Okuno
Favorite
(P 300) FEATURES AND OUTCOMES OF PATIENTS WITH GASTROINTESTINAL LEIYOMYOSARCOMA
Scott Okuno
Favorite
(P 424) AN OPEN-LABEL PHASE 1/2 STUDY OF DCC-3009 MONOTHERAPY IN PATIENTS (PTS) WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR (GIST)
Scott Okuno
Favorite
Olecki, Elizabeth

Roswell Park Comprehensive Cancer Center
(P 340) PREDICTORS OF LATE RECURRENCE AFTER SARCOMA SURGICAL RESECTION
Elizabeth Olecki
Favorite
Oliveira, Andre

Mayo Clinic
(P 309) RETROPERITONEAL LIPOMAS: MULTICENTER CLINICAL EXPERIENCE WITH AN EXTREMELY RARE DISEASE ENTITY
Andre Oliveira
Favorite
Oliveira, Luanna

A.C.Camargo Cancer Center
(P 132) MOLECULAR LANDSCAPE AND CLINICAL HETEROGENEITY OF BRAZILIAN CHONDROSARCOMAS: INSIGHTS FROM IDH, TERT, AND GENOME-WIDE ANALYSIS
Luanna Oliveira
Favorite
Oliveira, Luanna

AC Camargo Cancer Center
(P 155) BRCA2-MUTATED CONVENTIONAL CHONDROSARCOMA RESPONDING TO PARP INHIBITION: A CASE REPORT
Luanna Oliveira
Favorite
Olofsson-Bagge, Roger

Institute of Clinical Scinces/Sahlgrenska Academy
(P 124) ISOLATED LIMB PERFUSION AS LIMB SALVAGING TREATMENT; A SINGLE CENTRE RETROSPECTIVE STUDY
Roger Olofsson-Bagge
Favorite
Olshinkaa, Noam

Orthopedic Department, Sharett Institute for Oncology, Hadassah Medical Center & Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
(P 06) RAPID, POINT-OF-CARE DNA METHYLATION & MOLECULAR LANDSCAPE BASED SARCOMA CLASSIFICATION
Noam Olshinkaa
Favorite
Olvera Valencia, Mercedes

Instituto Politecnico Nacional
(P 39) BUB1 AN OVEREXPRESSED KINASE IN SARCOMA: FINDING NEW TARGET THERAPY FOR OSTEOSARCOMA, LIPOSARCOMA, SYNOVIAL SARCOMA AND LEIOMYOSARCOMA
Mercedes Olvera Valencia
Favorite
Olvera, Ramona

The Ohio State University
(P 221) QUALITATIVE ANALYSIS OF THE PERIOPERATIVE EXPERIENCE OF YOUNG ADULT PATIENTS UNDERGOING EXTREMITY SARCOMA SURGERY
Ramona Olvera
Favorite
Ong, Chin-Ann Johnny

National Cancer Center Singapore
(P 53) ESTABLISHMENT AND CHARACTERISATION OF LIPOSARCOMA-DERIVED CELLS AS RELEVANT PRE-CLINICAL MODELS FOR TARGET DISCOVERY
Chin-Ann Johnny Ong
Favorite
Onoe, Takuma

Hyogo Cancer Center
(P 192) OPTIMAL DOSING SCHEDULE OF SUNITINIB BASED ON PLATELET COUNT IN AN OLDER PATIENT WITH GASTROINTESTINAL STROMAL TUMOR
Takuma Onoe
Favorite
Onoe, Tsuyoshi

Shizuoka Cancer Center
(P 291) INTRA-ARTERIAL CHEMOTHERAPY WITH CONCOMITANT RADIATION THERAPY FOR UNRESECTABLE SARCOMA
Tsuyoshi Onoe
Favorite
Orbach, Daniel

SIREDO Oncology Center (Care, Innovation and Research for Children and AYA With Cancer), Institut Curie
(P 417) EFFICACY AND SAFETY OF LAROTRECTINIB (LARO) IN PATIENTS (PTS) WITH TRK FUSION SARCOMAS
Daniel Orbach
Favorite
Orford, Keith

Tagworks Pharmaceuticals
(P 415) A PHASE 1/2 TRIAL OF FOG-001, A FIRST-IN-CLASS DIRECT β-CATENIN:TCF4 INHIBITOR: SAFETY AND PRELIMINARY ANTITUMOR ACTIVITY IN PATIENTS WITH DESMOID TUMORS (DT)
Keith Orford
Favorite
Oristian, Kristianne

Sarcoma Foundation of America
(P 209) SARCOMA PATIENT COMMUNITY DATA COLLABORATION TO ADVANCE RESEARCH
Kristianne Oristian
Favorite
Orlando, Sarah

Fondazione Policlinico Universitario Campus Bio-Medico
(P 61) HER2 TARGETING IN CHORDOMA: PRECLINICAL INSIGHTS ON TRASTUZUMAB DERUXTECAN
Sarah Orlando
Favorite
Orlando, Sarah

Università Campus Bio-medico Roma
(P 183) ACTIONABLE GENOMICS IN GASTROINTESTINAL STROMAL TUMORS LACKING KIT OR PDGFRA MUTATIONS.
Sarah Orlando
Favorite
(P 236) EXCEPTIONAL RESPONSE TO COMBINATION IMMUNOTHERAPY WITH YH001 AND ENVAFOLIMAB IN METASTATIC SARCOMA.
Sarah Orlando
Favorite
(P 412) UNCOVERING HER2 OVEREXPRESSION IN SOFT TISSUE SARCOMAS (STS): INSIGHTS FROM THE CANCER GENOME ATLAS (TCGA)
Sarah Orlando
Favorite
(P 429) SINGLE-ARM, OPEN-LABEL PHASE II TRIAL OF XL092 (ZANZALINTINIB) IN PATIENTS WITH ADVANCED LEIOMYOSARCOMA: TRIAL IN PROGRESS
Sarah Orlando
Favorite
Orme, Lisa

Peter MacCallum Cancer Centre
(P 121) REAL-WORLD EXPERIENCE OF CABOZANTINIB MONOTHERAPY IN RELAPSED OR REFRACTORY OSTEOSARCOMA AND EWING SARCOMA: A SINGLE-CENTRE AUSTRALIAN STUDY
Lisa Orme
Favorite
Or, Omer

Orthopedic Department, Sharett Institute for Oncology, Hadassah Medical Center & Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
(P 06) RAPID, POINT-OF-CARE DNA METHYLATION & MOLECULAR LANDSCAPE BASED SARCOMA CLASSIFICATION
Omer Or
Favorite
Ortega-Izquierdo, Eugenia

Hospital Universitario Miguel Servet
(P 389) UNRESECTABLE AND METASTATIC DEDIFFERENTIATED LIPOSARCOMA (DDLPS): INSIGHTS FROM A MULTICENTER REAL-WORLD COHORT (RWC)
Eugenia Ortega-Izquierdo
Favorite
Ortiz Cruz, Eduardo

Hospital Universitario La Paz
(P 151) SHOULD WE USE ADJUVANT CHEMOTHERAPY IN PATIENTS WITH LOCALIZED DEDIFFERENTIATED CHONDROSARCOMA (DDCS) OF THE PELVIS? AN ANALYSIS BY THE PELVIC DDCS STUDY GROUP
Eduardo Ortiz Cruz
Favorite
Ortiz-Requena, Domenika

University of Miami
(P 147) CONVENTIONAL AND DEDIFFERENTIATED CHONDROSARCOMA; IS ENCHONDROMA THE PRECURSOR LESION?
Domenika Ortiz-Requena
Favorite
(P 327) INITIAL TREATMENT MODALITY AND RECURRENCE IN NON-METASTATIC LEIOMYOSARCOMA: A RETROSPECTIVE COHORT STUDY
Domenika Ortiz-Requena
Favorite
(P 333) METABOLIC SYNDROME CORRELATION WITH LIPOSARCOMA INCIDENCE AND OUTCOMES: A RETROSPECTIVE ANALYSIS.
Domenika Ortiz-Requena
Favorite
Osman, Noha

The University of Texas MD Anderson Cancer Center
(P 172) COMPARISON OF CELL SEGMENTATION METHODS IN SOFT TISSUE SARCOMA (STS) SPATIAL PROTEOMIC DATASETS
Noha Osman
Favorite
(P 242) IMMUNE PROFILING OF UNDIFFERENTIATED PLEOMORPHIC SARCOMAS REVEALS DISTINCT PROGNOSTIC SUBGROUPS
Noha Osman
Favorite
Ossiani, Tara

MGH
(P 392) CLASSIFICATION AND DIFFERENTIATIONOF MYXOID LIPOSARCOMA AND MYXOMA WITH MACHINE LEARNING
Tara Ossiani
Favorite
(P 392) DIFFERENTIATION OF MYXOMA AND MYXOID LIPOSARCOMA BASED ON RADIOMICS PHENOTYPES
Tara Ossiani
Favorite
Otero Norza, Diana

Dr. Rafael Angel Calderón Guardia.
(P 306) PROGNOSTIC NUTRITIONAL INDEX PREDICTS MAJOR POSTOPERATIVE COMPLICATIONS IN RETROPERITONEAL SARCOMA: RESULTS FROM THE LATAMSARC COHORT
Diana Otero Norza
Favorite
Oton, Ana

SpringWorks Therapeutics
(P 413) EFFICACY OF NIROGACESTAT IN PATIENTS WITH DESMOID TUMORS AND PRESENCE OR ABSENCE OF POOR PROGNOSTIC FACTORS: POST HOC ANALYSES OF THE PHASE 3 DEFI TRIAL
Ana Oton
Favorite
(P 442) TRIAL IN PROGRESS: A SINGLE-ARM, OPEN-LABEL PHASE 4 TRIAL OF NIROGACESTAT IN ADULT PREMENOPAUSAL FEMALES WITH DESMOID TUMORS
Ana Oton
Favorite
O'Toole, Gary

St Vincent's University Hospital
(P 211) HEALTH-RELATED QUALITY OF LIFE IN IRISH SARCOMA PATIENTS
Gary O'Toole
Favorite
(P 213) FINANCIAL TOXICITY IN IRISH SARCOMA CARE: A SINGLE-CENTRE ANALYSIS
Gary O'Toole
Favorite
O'Toole, Riley

Cleveland Clinic
(P 220) THE IMPACT OF WOUND HEALING COMPLICATIONS ON PATIENT-REPORTED OUTCOMES FOLLOWING SOFT TISSUE SARCOMA SURGERY
Riley O'Toole
Favorite
(P 316) AREA DEPRIVATION INDEX (ADI) AND OUTCOMES IN LOCALIZED SOFT TISSUE SARCOMA: DO SOCIAL DETERMINANTS INFLUENCE SURVIVAL?
Riley O'Toole
Favorite
(P 355) CLASSIFYING WOUND HEALING COMPLICATIONS IN SURGICALLY TREATED EXTREMITY SOFT TISSUE SARCOMA
Riley O'Toole
Favorite
Ottestad, Anine

Oslo University Hospital
(P 200) DISSECTING INTRATUMORAL HETEROGENEITY IN GIST USING SPATIAL TRANSCRIPTOMICS
Anine Ottestad
Favorite
Oudeh, Ahmad

Memorial Sloan Kettering Cancer Center
(P 273) RADIOMIC PREDICTORS OF SPONTANEOUS PNEUMOTHORAX DURING TYROSINE KINASE INHIBITOR THERAPY FOR LUNG METASTASES
Ahmad Oudeh
Favorite
Ou, Jianhong

Duke University
(P 126) SINGLE-CELL RNA SEQUENCING AND PROTEOMIC SPATIAL PROFILING REVEAL COMPLEX TUMOR MICROENVIRONMENT AND NOVEL IMMUNE INTERACTIONS IN CHONDROSARCOMA
Jianhong Ou
Favorite
Oyem, Precious

Cleveland Clinic
(P 220) THE IMPACT OF WOUND HEALING COMPLICATIONS ON PATIENT-REPORTED OUTCOMES FOLLOWING SOFT TISSUE SARCOMA SURGERY
Precious Oyem
Favorite
Ozaki, Toshifumi

Okayama University Hospital
(P 79) AGE-BASED TREATMENT PATTERNS AND OUTCOMES OF LOCALIZED HIGH-GRADE OSTEOSARCOMA FROM A NATIONWIDE DATABASE: WHAT IS THE OPTIMAL STRATEGY FOR PATIENTS OLDER THAN 40 YEARS?
Toshifumi Ozaki
Favorite
Ozaniak Strizova, Zuzana

Department of Immunology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
(P 243) CLINICAL SIGNIFICANCE OF TUMOR-INFILTRATING IMMUNE CELL SUBSETS IN THE RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS AND LEIOMYOSARCOMAS
Zuzana Ozaniak Strizova
Favorite
Ozaniak, Andrej

Third Department of Surgery, 1st Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
(P 243) CLINICAL SIGNIFICANCE OF TUMOR-INFILTRATING IMMUNE CELL SUBSETS IN THE RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS AND LEIOMYOSARCOMAS
Andrej Ozaniak
Favorite